Waldenstrom's Macroglobulinaemia - Pipeline Insight, 2022

This “Waldenstrom's macroglobulinaemia - Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Waldenstrom's macroglobulinaemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Waldenstrom's macroglobulinaemia Understanding

Waldenstrom's macroglobulinaemia: Overview

Waldenstrom's macroglobulinaemia is a rare type of cancer that begins in the white blood cells. In this the bone marrow produces too many white blood cells that crowd out the normal healthy blood cells. Waldenstrom macroglobulinaemia is considered a type of non-Hodgkin's lymphoma. It's is also sometimes called lymphoplasmacytic lymphoma. Waldenstrom macroglobulinaemia is slow growing and may not cause signs and symptoms for many years. When they occur the symptoms may include: easy bruising, fatigue, weight loss, fever, numbness in hands and feet's, change in vision and shortness of breath. What causes Waldenstrom's macroglobulinaemia is still not clear. The disease generally begins with one abnormal white blood cell that develops errors (mutations) in its genetic code. The treatment options may include: chemotherapy, Plasma exchange, Targeted Therapy, Biological therapy and Bone marrow transplant.

"Waldenstrom's macroglobulinaemia - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Waldenstrom's macroglobulinaemia pipeline landscape is provided which includes the disease overview and Waldenstrom's macroglobulinaemia treatment guidelines. The assessment part of the report embraces, in depth Waldenstrom's macroglobulinaemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Waldenstrom's macroglobulinaemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Waldenstrom's macroglobulinaemia R&D. The therapies under development are focused on novel approaches to treat/improve Waldenstrom's macroglobulinaemia.

Waldenstrom's macroglobulinaemia Emerging Drugs Chapters

This segment of the Waldenstrom's macroglobulinaemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Waldenstrom's macroglobulinaemia Emerging Drugs

Obinutuzumab : Roche

Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody (mAb), has been described as being more effective than rituximab in low-grade lymphoid malignancies, including in unfit treatment-naive patients with chronic lymphocytic leukemia and in follicular lymphoma, resulting in longer PFS than with rituximab-based therapy.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Waldenstrom Macroglobulinemia.

ABT199: Abbvie

ABT-199 (vnetoclax), which is a Bcl-2 inhibitor. Bcl-2 is an apoptosis regulator expressed in high levels in leukemia cells, and it is responsible for the prolonged survival of these cells. Venetoclax will block and modulate the activity of Bcl-2. The clinical trials for ABT199 are being evaluated in phase II stage of development for the treatment of Waldenstrom's macroglobulinaemia in collaboration with Dana-Farber Cancer Institute.

Waldenstrom's macroglobulinaemia: Therapeutic Assessment

This segment of the report provides insights about the different Waldenstrom's macroglobulinaemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Waldenstrom's macroglobulinaemia

There are approx. 25+ key companies which are developing the therapies for Waldenstrom's macroglobulinaemia. The companies which have their Waldenstrom's macroglobulinaemia drug candidates in the most advanced stage, i.e. Phase II include, Roche.

Phases

The report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Waldenstrom's macroglobulinaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Subcutaneous
• Intravenous
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Waldenstrom's macroglobulinaemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Waldenstrom's macroglobulinaemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Waldenstrom's macroglobulinaemia drugs.

Waldenstrom's macroglobulinaemia Report Insights

• Waldenstrom's macroglobulinaemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Waldenstrom's macroglobulinaemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Waldenstrom's macroglobulinaemia drugs?
• How many Waldenstrom's macroglobulinaemia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Waldenstrom's macroglobulinaemia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Waldenstrom's macroglobulinaemia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Waldenstrom's macroglobulinaemia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Amgen
• Abbvie
• Roche
• Bristol-Myers Squibb
• Mavorixafor

^- TransThera Sciences

Key Products

• Carfilzomib
• ABT199
• Obinutuzumab
• Dasatinib
• X4 Pharmaceuticals
• TT-01488

This product will be delivered within 1-3 business days.